德国拜耳利伐沙班用药指导

In recent years, new anticoagulant drugs Factor Xa (FXa) inhibitors have received more and more attention among anticoagulant drugs, among which they are representative drugs of FXa inhibitors. Rivaroxaban is a small molecule oral anticoagulant jointly developed by Bayer and Johnson & Johnson, which can effectively relieve the pain of patients with venous thrombosis.

Bayer, headquartered in Leverkusen, Germany, has 750 production plants in 200 locations on six continents; it has 120,000 employees and 350 branches in almost every country in the world. Polymers, medicine and health care, chemical industry and agriculture are the company's four pillar industries. The company's product categories exceed 10,000 types. The company has produced aspirin, heroin and other products.

How should I take rivaroxaban produced by Bayer in Germany?

The recommended dose is oral rivaroxaban 10 mg once daily. If the wound has stopped bleeding, the first medication should be administered between 6 and 10 hours after surgery. The length of treatment is determined by each patient's risk of VTE, i.e. by the type of orthopedic surgery the patient has undergone. For patients undergoing major hip surgery, a recommended course of treatment is 5 weeks. For patients undergoing major knee surgery, a recommended course of treatment is 2 weeks. If a dose is missed, the patient should take rivaroxaban immediately and continue taking it once daily the next day. Patients can take rivaroxaban with a meal or on its own.

Rivaroxaban is available as red film-coated tablets. Its main active ingredient is: Rivaroxaban, a highly selective oral drug that directly inhibits factor Xa. Clinically indicated for the prevention of venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery. Its main mechanism of action is: inhibitory factor Xa can interrupt the endogenous and exogenous pathways of the coagulation cascade and inhibit the generation of thrombin and thrombosis.

Due to the pharmacodynamic properties of rivaroxaban, overdose may result in bleeding complications. At the same time, some subgroups of patients are at higher risk of bleeding, such as patients with liver damage and kidney damage. After initiation of treatment, these patients should be monitored closely for signs of bleeding complications.

The above is the content of medication guidance, I hope it can help you.

Recommended related hot articles: /newsDetail/90162.html